Microbiology (medical), Immunology and Microbiology, Cancer Research, Software
21
Scopus Publications
558
Scholar Citations
9
Scholar h-index
9
Scholar i10-index
Scopus Publications
Long non-coding RNA PCAT18 defines a leukemia-specific regulatory network in pediatric T-ALL F. Altieri, G. Pecoraro, V. Costabile, R. Penta de Vera d’Aragona, G. Becchimanzi, G. Beneduce, R. Parasole, G. Smaldone Scientific Reports, 2026 Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators of gene expression across various levels, including transcriptional, post-transcriptional, and epigenetic mechanisms. In pediatric T-cell acute lymphoblastic leukemia (T-ALL), dysregulated lncRNA expression contributes to altered cell proliferation, apoptosis resistance, treatment response, and disease progression. Our previous work identified a distinct lncRNA signature capable of differentiating T-ALL from B-ALL, highlighting their diagnostic potential. In our work, we focused on the lncRNA called PCAT18. We used RNA-seq analysis on 13 patients with T-ALL in comparison to cord blood cells. We performed a preliminarly in silico analysis throught WGCNA to reveal interesting co-expression network of target lncRNA. PCAT18 silencing in two T-ALL cell models allowed to investigate its functional role in physiological and pathological states. Finally, RNA-seq analyses of PCAT18 silenced cell line in comparison with control cell line was carried out to identify and confirm pathways significantly altered by its absence. Our network analysis (WGCNA) revealed that PCAT18 is highly connected within a module strongly associated with the T-ALL phenotype. Functional assays in JURKAT cells demonstrated that PCAT18 knockdown paradoxically enhanced proliferation, induced G1 phase accumulation, reduced p27 expression, and upregulated Cyclin B, suggesting disrupted checkpoint control and uncoordinated cell cycle progression. Additionally, deregulation of FOXP3, NOTCH3, HSP90AA1, and HSPA8 implicated PCAT18 in stress response pathways and lineage identity maintenance. These findings support a tumor-suppressive role for PCAT18 in T-ALL, in contrast to its oncogenic role in solid tumors. PCAT18 appears to operate at the intersection of transcriptional regulation, cell cycle control, and stress adaptation. Its disease- and lineage-specific expression makes it a promising candidate for biomarker development and therapeutic targeting in pediatric T-ALL. This study expands our understanding of lncRNA biology in leukemia and uncovers novel regulatory mechanisms in T-ALL pathogenesis.
Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico-Pathological and Molecular Characterization of a Case Series Sabrina Rossi, Sabina Barresi, Isabella Giovannoni, Silvia Genovese, Valentino Costabile, Alessandra Stracuzzi, Silvia Vallese, Chantal Tancredi, Andrea Diociaiuti, Giuseppe M. Milano, Andrea Ferrari, Patrizia Bertolini, Stefano Chiaravalli, Emanuele Agolini, Gemma D'Elia, Giorgia Catino, Licia Martucci, Marta Cajozzo, Fabio Dell'Otto, Gianni Bisogno, Alessandro Crocoli, Evelina Miele, Giovanna Zambruno, Maria Debora De Pasquale, Mario Zama, Antonio Novelli, May El Hachem, Viola Alesi, Rita Alaggio Pigment Cell and Melanoma Research, 2026 Giant congenital melanocytic nevi (GCMN) are benign mosaic disorders that may give rise to various tumor types through incompletely understood mechanisms. We characterized a series of two melanomas and four mesenchymal tumors (two embryonal rhabdomyosarcomas, one small round cell sarcoma, one low‐grade mesenchymal tumor) arising in GCMN. Median onset age was 3.5 years and 3 months for melanoma and mesenchymal tumor patients, respectively. Both melanoma patients succumbed within 27 months from diagnosis, whereas no patients progressed in the mesenchymal group (median follow‐up 46 months). NRAS Q61, BRAF V600E mutation, and a novel in frame BIN1::BRAF fusion were detected in four, one, and one cases, respectively, with a higher variant allele frequency in the tumors compared with the matched GCMN. Copy number alterations and/or copy‐neutral loss of heterozygosity were exclusively found in the tumors in all cases. An inactivating ASXL1 variant and an in‐frame KDM5B::LPGAT1 fusion were identified in one melanoma; paternal disomy of 11p15.5 in both embryonal rhabdomyosarcomas. Mesenchymal tumors and melanomas showed distinct transcriptional profiles enriched in muscle and synapse organization and epidermal differentiation genes, respectively.
Arthrospira Platensis Attenuates Endothelial Inflammation and Monocyte Activation Ilaria Leone, Valentino Costabile, Giovanni Smaldone, Monica Franzese, Andrea Soricelli, et al. International Journal of Molecular Sciences, 2025 Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality in industrialized countries. Coronary artery disease (CAD) represents the most prevalent form of cardiovascular disease and remains a leading cause of morbidity, mortality, and long-term disability worldwide. Therefore, the identification of early biomarkers and clarification of the mechanism of action of pharmacological adjuvants is urgently needed. Nutraceuticals such as Arthrospira platensis (commonly known as spirulina) have emerged as promising modulators for their notable vascular anti-inflammatory properties. In this study, we provide novel evidence of the anti-inflammatory and anti-atherosclerotic potential of Arthrospira platensis toward endothelial cells and immune interactions, combining in vitro assays with bioinformatic profiling. Spirulina treatment significantly attenuated endothelial and angiogenic activation, reducing pro-inflammatory cytokine and VEGFA/VEGFR2 expression. Additionally, it also decreased the activation and adhesion capabilities of THP-1 monocytic cell lines. Through computational analysis of the complex molecular mixture present in Arthrospira platensis, we have identified a subset of compounds exhibiting high structural similarity to CHEMBL3559503, a well-characterized synthetic molecule with dual activity as a TLR9 agonist and anti-angiogenic agent. This represents a novel insight, suggesting that spirulina may serve as a natural source of analogues capable of modulating both immune and angiogenic pathways. These results highlight Arthrospira platensis as a promising candidate nutraceutical for targeting endothelial/immune crosstalk in the context of atherosclerosis prevention, offering both mechanistic insights and translational potential.
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study Angela Mastronuzzi, Rita Carsetti, Maria Antonietta De Ioris, Chiara Agrati, Giada Del Baldo, Cristina Russo, Maria Giuseppina Cefalo, Pietro Merli, Carlo Federico Perno, Vito Andrea dell'Anna, Annalisa Serra, Veronica Bordoni, Eva Piano Mortari, Valentina Marcellini, Christian Albano, Giulia Linardos, Valentino Costabile, Matilde Sinibaldi, Marika Guercio, Stefano di Cecca, Concetta Quintarelli, Franco Locatelli Heliyon, 2024 Immunocompromised children are at risk of developing severe COVID-19 infection. We conducted a pilot prospective study to evaluate the impact of cancer treatment and stem cell transplantation on immunogenicity of two doses of BNT162b2 vaccine in pediatric patients. Humoral, B- and T-cell responses to the BNT162b2 vaccine were assessed before, after the first and the second dose in patients aged 5-12 years (n = 35) and in a group of healthy donors (HD, n = 12). Patients were divided in three groups: solid tumors (ST, n = 11), hematological malignancies (HM, n = 14) and Hematopoietic Stem Cell Transplantation (HSCT) recipients (n = 10). After two vaccine doses, the seroconversion rate was 79.3 % (72.7 % in ST, 66.7 % in HM and 100 % in HSCT). The antibodies production was not associated to the presence of memory B and T-cells. Memory B-cells were measurable in 45.5 % ST, 66.6 % HSCT and in 22.0 % HM. The specific T-cell response was observed in most ST (81.8 %) and HSCT (85.7 %) patients and at lesser extent in those with HM (55.5 %). The combination of all immunological parameters (antibodies, memory B and T cells) showed that a significant fraction of HM (33.3 %) and ST (18.2 %) patients completely failed to respond to vaccination. Although able to produce antibodies, 11.1 % of HM and 27.3 % of ST had no B- and T-cell memory. HSCT subgroup showed the best immune function, with 80 % complete response and optimal T-cell function. Combination of anti-RBD antibody, and specific memory B- and T-cell responses represents a reliable read-out of vaccine immune efficacy in frail patients.
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study Francesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, Domenico Di Carlo, Valentino Costabile, Martina Ranzenigo, Franco Maggiolo, Antonella Castagna, Anna Paola Callegaro, Alessia Zoncada, Stefania Paolucci, Valeria Micheli, Silvia Renica, Antonia Bezencheck, Barbara Rossetti, Maria Mercedes Santoro AIDS Research and Human Retroviruses, 2024 Despite effective antiretroviral therapies (ART), a subset of people living with HIV (PLWH) still experience low-level viremia (LLV, i.e. 50-1000 copies/mL). The present study compared PLWH experiencing LLV to those maintaining viral suppression (VS) and explored the potential impact of pre-existing drug resistance and other factors on LLV. We conducted a retrospective, 1:1 matched case-control study within a cohort of drug-experienced virologically suppressed subjects from the Italian ARCA database, followed in the period 2009-2019. Cases were individuals experiencing LLV, while controls were those who maintained VS. Matching was for calendar year of first ART regimen. Pre-existing drug resistance was calculated as cumulative genotypic susceptibility score (GSS) according to regimen administered at the observational period start. To explore the effect of cumulative GSS, treated as a binary variable (≥2 and <2) and other factors on LLV, we performed a logistic regression analysis. Within a main population of 3,455 PLWH, 337 cases were selected. Cases were comparable to the controls for both gender and age. However, cases showed that they'd experienced a longer time since HIV diagnosis, a higher number of drugs previously administered, lower baseline CD4+ T cells count and a higher zenith viral load (VL). By multivariate analysis, we found that higher zenith VL (aOR [95% C.I.] 1.30 [1.14-1.48]), a cumulative usage of both PI (aOR [95% CI]: 2.03 [1.19-3.48]) and InSTI (aOR [95% CI]: 2.23 [1.47-3.38]) and a cumulative GSS <2 (aOR [95% CI] 0.67 [0.46-0.98]), were associated with a higher risk in developing LLV. In current high efficacy ART era, in drug-experienced PLWH the predictors of increased risk of LLV were the presence of pre-existing drug resistance, higher zenith viral load, and previous PI, and InSTI exposure.
PATZ1-Rearranged Tumors of the Central Nervous System: Characterization of a Pediatric Series of Seven Cases Sabrina Rossi, Sabina Barresi, Giovanna Stefania Colafati, Silvia Genovese, Chantal Tancredi, Valentino Costabile, Sara Patrizi, Isabella Giovannoni, Sofia Asioli, Pietro Luigi Poliani, Marina Paola Gardiman, Antonello Cardoni, Giada Del Baldo, Manila Antonelli, Francesca Gianno, Eleonora Piccirilli, Giorgia Catino, Licia Martucci, Denise Quacquarini, Francesco Toni, Fraia Melchionda, Elisabetta Viscardi, Mino Zucchelli, Sandro Dal Pos, Enza Gatti, Roberto Liserre, Elisabetta Schiavello, Francesca Diomedi-Camassei, Andrea Carai, Angela Mastronuzzi, Marco Gessi, Caterina Giannini, Antonio Novelli, Andrea Onetti Muda, Evelina Miele, Viola Alesi, Rita Alaggio Modern Pathology, 2024
A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia Rossana Scutari, Valeria Fox, Maria Antonietta De Ioris, Vanessa Fini, Annarita Granaglia, Valentino Costabile, Luna Colagrossi, Cristina Russo, Angela Mastronuzzi, Franco Locatelli, Carlo Federico Perno, Claudia Alteri BMC Infectious Diseases, 2023 Background Since its emergence in November 2021, SARS-CoV-2 Omicron clade has quickly become dominant, due to its increased transmissibility and immune evasion. Different sublineages are currently circulating, which differ in mutations and deletions in regions of the SARS-CoV-2 genome implicated in the immune response. In May 2022, BA.1 and BA.2 were the most prevalent sublineages in Europe, both characterized by ability of evading natural acquired and vaccine-induced immunity and of escaping monoclonal antibodies neutralization. Case presentation A 5-years old male affected by B-cell acute lymphoblastic leukemia in reinduction was tested positive for SARS-CoV-2 by RT-PCR at the Bambino Gesù Children Hospital in Rome in December 2021. He experienced a mild COVID-19 manifestation, and a peak of nasopharyngeal viral load corresponding to 15.5 Ct. Whole genome sequencing identified the clade 21 K (Omicron), sublineage BA.1.1. The patient was monitored over time and tested negative for SARS-CoV-2 after 30 days. Anti-S antibodies were detected positive with modest titre (3.86 BAU/mL), while anti-N antibodies were negative. 74 days after the onset of the first infection and 23 days after the last negative test, the patient was readmitted to hospital with fever, and tested positive for SARS-CoV-2 by RT-PCR (peak of viral load corresponding to 23.3 Ct). Again, he experienced a mild COVID-19. Whole genome sequencing revealed an infection with the Omicron lineage BA.2 (21L clade). Sotrovimab administration was started at the fifth day of positivity, and RT-PCR negativity occurred 10 days later. Surveillance SARS-CoV-2 RT-PCR were persistently negative, and in May 2022, anti-N antibodies were found positive and anti-S antibodies reached titres > 5000 BAU/mL. Conclusions By this clinical case, we showed that SARS-CoV-2 reinfection within the Omicron clade can occur and can be correlated to inadequate immune responses to primary infection. We also showed that the infection’s length was shorter in the second respect to first episode, suggesting that pre-existing T cell-mediated immunity, though not preventing re-infection, might have limited the SARS-CoV-2 replication capacity. Lastly, Sotrovimab treatment retained activity against BA.2, probably accelerating the viral clearance in the second infectious episode, after which seroconversion and increase of anti-S antibodies titres were observed.
Identification of the blaOXA-23 Gene in the First Mucoid XDR Acinetobacter baumannii Isolated from a Patient with Cystic Fibrosis Martina Rossitto, Gianluca Vrenna, Vanessa Tuccio Guarna Assanti, Nour Essa, Maria Luisa De Santis, Annarita Granaglia, Vanessa Fini, Valentino Costabile, Manuela Onori, Luca Cristiani, Alessandra Boni, Renato Cutrera, Carlo Federico Perno, Paola Bernaschi Journal of Clinical Medicine, 2023 Acinetobacter baumannii is one of the pathogens most involved in health care-associated infections in recent decades. Known for its ability to accumulate several antimicrobial resistance mechanisms, it possesses the oxacillinase blaoxa-23, a carbapenemase now endemic in Italy. Acinetobacter species are not frequently observed in patients with cystic fibrosis, and multidrug-resistant A. baumannii is a rare event in these patients. Non-mucoid A. baumannii carrying the blaoxa-23 gene has been sporadically detected. Here, we describe the methods used to detect blaoxa-23 in the first established case of pulmonary infection via a mucoid strain of A. baumannii producing carbapenemase in a 24-year-old cystic fibrosis patient admitted to Bambino Gesù Children’s Hospital in Rome, Italy. This strain, which exhibited an extensively drug-resistant antibiotype, also showed a great ability to further increase its resistance in a short time.
The Prevalence of Carbapenemase-Producing Microorganisms and Use of Novel Cephalosporins for the Treatment of Severe Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria in a Pediatric Cardiac Intensive Care Unit Costanza Tripiciano, Lorenza Romani, Stefania Mercadante, Laura Cursi, Martina Di Giuseppe, Francesca Ippolita Calo Carducci, Tiziana Fragasso, Luca Di Chiara, Cristiana Garisto, Annamaria Sisto, Leonardo Vallesi, Valentino Costabile, Laura Lancella, Paola Bernaschi, Maia De Luca Antibiotics, 2023 Background: The spread of carbapenem-resistant organisms (CROs) is an increasingly serious threat globally, especially in vulnerable populations, such as intensive care unit (ICU) patients. Currently, the antibiotic options for CROs are very limited, particularly in pediatric settings. We describe a cohort of pediatric patients affected by CRO infections, highlighting the important changes in carbapenemase production in recent years and comparing the treatment with novel cephalosporins (N-CEFs) to Colistin-based regimens (COLI). Methods: All patients admitted to the cardiac ICU of the Bambino Gesù Children’s Hospital in Rome during the 2016–2022 period with an invasive infection caused by a CRO were enrolled. Results: The data were collected from 42 patients. The most frequently detected pathogens were Pseudomonas aeruginosa (64%), Klebsiella pneumoniae (14%) and Enterobacter spp. (14%). Thirty-three percent of the isolated microorganisms were carbapenemase producers, with a majority of VIM (71%), followed by KPC (22%) and OXA-48 (7%). A total of 67% of patients in the N-CEF group and 29% of patients in the comparative group achieved clinical remission (p = 0.04). Conclusion: The increase over the years of MBL-producing pathogens in our hospital is challenging in terms of therapeutic options. According to the present study, N-CEFs are a safe and effective option in pediatric patients affected by CRO infections.
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients Claudia Alteri, Valeria Fox, Rossana Scutari, Giulia Jole Burastero, Sara Volpi, Matteo Faltoni, Vanessa Fini, Annarita Granaglia, Sara Esperti, Altea Gallerani, Valentino Costabile, Beatrice Fontana, Erica Franceschini, Marianna Meschiari, Andrea Campana, Stefania Bernardi, Alberto Villani, Paola Bernaschi, Cristina Russo, Giovanni Guaraldi, Cristina Mussini, Carlo Federico Perno Communications Biology, 2022
Long non-coding RNA PCAT18 defines a leukemia-specific regulatory network in pediatric T-ALL F Altieri, G Pecoraro, V Costabile, RP de Vera d’Aragona, G Becchimanzi, ... Scientific Reports , 2026 2026
Clinical sampling challenges in diagnosing severe respiratory viral infections. A Piralla, C Russo, S Ranno, C Acciarri, S Menzo, SU Renteria, ... Chest , 2026 2026
Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico‐Pathological and Molecular Characterization of a Case Series S Rossi, S Barresi, I Giovannoni, S Genovese, V Costabile, A Stracuzzi, ... Pigment Cell & Melanoma Research 39 (1), e70071 , 2026 2026
SOX11 is frequently expressed in ETV6::NTRK3 -rearranged infantile fibrosarcoma and congenital mesoblastic nephroma F Malik, KS Provine, SC Koo, T Santiago, CA Tucker, V Costabile, ... Virchows Archiv, 1-8 , 2025 2025 Citations: 1
Arthrospira Platensis Attenuates Endothelial Inflammation and Monocyte Activation I Leone, V Costabile, G Smaldone, M Franzese, A Soricelli, A D’Agostino International Journal of Molecular Sciences 26 (16), 7844 , 2025 2025 Citations: 2
Comprehensive analysis of gene expression profiles in paediatric myofibroblastic neoplasms E Rullo Università degli Studi di Roma" La Sapienza" , 2025 2025 Citations: 1
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study A Mastronuzzi, R Carsetti, MA De Ioris, C Agrati, G Del Baldo, C Russo, ... Heliyon 10 (14) , 2024 2024 Citations: 4
Factors associated with low-level viremia in people living with HIV in the Italian antiviral response cohort analysis cohort: a case–control study F Lombardi, E Bruzzesi, YR Bouba, D Di Carlo, V Costabile, M Ranzenigo, ... AIDS Research and Human Retroviruses 40 (2), 80-89 , 2024 2024 Citations: 8
PATZ1-rearranged tumors of the central nervous system: characterization of a pediatric series of seven cases S Rossi, S Barresi, GS Colafati, S Genovese, C Tancredi, V Costabile, ... Modern Pathology 37 (2), 100387 , 2024 2024 Citations: 15
Identification of the bla OXA-23 Gene in the First Mucoid XDR Acinetobacter baumannii Isolated from a Patient with Cystic Fibrosis M Rossitto, G Vrenna, V Tuccio Guarna Assanti, N Essa, ML De Santis, ... Journal of Clinical Medicine 12 (20), 6582 , 2023 2023 Citations: 5
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study. F Lombardi, E Bruzzesi, YR Bouba, D Di Carlo, V Costabile, M Ranzenigo, ... AIDS Research and Human Retroviruses 40 (2), 80-89 , 2023 2023
P274 Identification of blaOXA-23 in a mucoid XDR Acinetobacter baumannii isolated from a patient with cystic fibrosis M Rossitto, G Vrenna, VTG Assanti, N Essa, ML De Santis, M Nespoli, ... Journal of Cystic Fibrosis 22, S149 , 2023 2023
The prevalence of carbapenemase-producing microorganisms and use of novel cephalosporins for the treatment of severe infections caused by carbapenem-resistant gram-negative … C Tripiciano, L Romani, S Mercadante, L Cursi, M Di Giuseppe, ... Antibiotics 12 (5), 796 , 2023 2023 Citations: 8
A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia R Scutari, V Fox, MA De Ioris, V Fini, A Granaglia, V Costabile, ... BMC Infectious Diseases 23 (1), 133 , 2023 2023 Citations: 3
Evidence of pediatric sepsis caused by a drug resistant Lactococcus garvieae contaminated platelet concentrate L Colagrossi, V Costabile, R Scutari, M Agosta, M Onori, L Mancinelli, ... Emerging Microbes & Infections 11 (1), 1325-1334 , 2022 2022 Citations: 15
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients C Alteri, V Fox, R Scutari, GJ Burastero, S Volpi, M Faltoni, V Fini, ... Communications Biology 5 (1), 1376 , 2022 2022 Citations: 27
Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients L Colagrossi, V Costabile, R Scutari, V Cento, L Coltella, A Reale, ... Frontiers in Microbiology 13, 999783 , 2022 2022 Citations: 5
Genomic evolution of SARS-CoV-2 in Molnupiravir-treated patients compared to Paxlovid-treated and drug-naïve patients: A proof-of-concept study C Alteri, V Fox, R Scutari, GJ Burastero, S Volpi, M Faltoni, V Fini, ... 2022 Citations: 4
Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation C Alteri, R Scutari, V Costabile, L Colagrossi, KY La Rosa, E Agolini, ... Scientific Reports 12, 12814 , 2022 2022 Citations: 3
Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation C Alteri, R Scutari, V Costabile, L Colagrossi, K Yu La Rosa, E Agolini, ... Scientific reports 12 (1), 10194 , 2022 2022 Citations: 35
MOST CITED SCHOLAR PUBLICATIONS
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy C Alteri, V Cento, A Piralla, V Costabile, M Tallarita, L Colagrossi, ... Nature communications 12 (1), 434 , 2021 2021.0 Citations: 142
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients C Alteri, V Cento, M Antonello, L Colagrossi, M Merli, N Ughi, S Renica, ... PloS one 15 (9), e0236311 , 2020 2020.0 Citations: 141
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients V Cento, L Colagrossi, A Nava, A Lamberti, S Senatore, G Travi, ... The Journal of infection 81 (3), e90 , 2020 2020.0 Citations: 87
Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation C Alteri, R Scutari, V Costabile, L Colagrossi, K Yu La Rosa, E Agolini, ... Scientific reports 12 (1), 10194 , 2022 2022.0 Citations: 35
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients C Alteri, V Fox, R Scutari, GJ Burastero, S Volpi, M Faltoni, V Fini, ... Communications Biology 5 (1), 1376 , 2022 2022.0 Citations: 27
Nasopharyngeal SARS-CoV-2 load at hospital admission as a predictor of mortality C Alteri, V Cento, M Vecchi, L Colagrossi, D Fanti, C Vismara, M Puoti, ... Clinical Infectious Diseases 72 (10), 1868-1869 , 2021 2021.0 Citations: 17
PATZ1-rearranged tumors of the central nervous system: characterization of a pediatric series of seven cases S Rossi, S Barresi, GS Colafati, S Genovese, C Tancredi, V Costabile, ... Modern Pathology 37 (2), 100387 , 2024 2024.0 Citations: 15
Evidence of pediatric sepsis caused by a drug resistant Lactococcus garvieae contaminated platelet concentrate L Colagrossi, V Costabile, R Scutari, M Agosta, M Onori, L Mancinelli, ... Emerging Microbes & Infections 11 (1), 1325-1334 , 2022 2022.0 Citations: 15
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy. Italy Nat Commun. 2021; 12: 434 C Alteri, V Cento, A Piralla, V Costabile, M Tallarita, L Colagrossi, ... Epub 2021/01/21.[Europe PMC free article][Abstract][CrossRef][Google Scholar] , 0 Citations: 14
Factors associated with low-level viremia in people living with HIV in the Italian antiviral response cohort analysis cohort: a case–control study F Lombardi, E Bruzzesi, YR Bouba, D Di Carlo, V Costabile, M Ranzenigo, ... AIDS Research and Human Retroviruses 40 (2), 80-89 , 2024 2024.0 Citations: 8
The prevalence of carbapenemase-producing microorganisms and use of novel cephalosporins for the treatment of severe infections caused by carbapenem-resistant gram-negative … C Tripiciano, L Romani, S Mercadante, L Cursi, M Di Giuseppe, ... Antibiotics 12 (5), 796 , 2023 2023.0 Citations: 8
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study R Scutari, V Costabile, L Galli, MC Bellocchi, L Carioti, S Barbaliscia, ... Viruses 13 (7), 1403 , 2021 2021.0 Citations: 8
Hot spot mapping of protein surfaces with TEMPOL: Bovine pancreatic RNase A as a model system N Niccolai, E Morandi, S Gardini, V Costabile, R Spadaccini, O Crescenzi, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1865 (2), 201-207 , 2017 2017.0 Citations: 8
Identification of the bla OXA-23 Gene in the First Mucoid XDR Acinetobacter baumannii Isolated from a Patient with Cystic Fibrosis M Rossitto, G Vrenna, V Tuccio Guarna Assanti, N Essa, ML De Santis, ... Journal of Clinical Medicine 12 (20), 6582 , 2023 2023.0 Citations: 5
Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients L Colagrossi, V Costabile, R Scutari, V Cento, L Coltella, A Reale, ... Frontiers in Microbiology 13, 999783 , 2022 2022.0 Citations: 5
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat. Commun. 12 (1), 434 C Alteri, V Cento, A Piralla, V Costabile, M Tallarita, L Colagrossi, ... 2021.0 Citations: 5
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study A Mastronuzzi, R Carsetti, MA De Ioris, C Agrati, G Del Baldo, C Russo, ... Heliyon 10 (14) , 2024 2024.0 Citations: 4
Genomic evolution of SARS-CoV-2 in Molnupiravir-treated patients compared to Paxlovid-treated and drug-naïve patients: A proof-of-concept study C Alteri, V Fox, R Scutari, GJ Burastero, S Volpi, M Faltoni, V Fini, ... 2022.0 Citations: 4
A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia R Scutari, V Fox, MA De Ioris, V Fini, A Granaglia, V Costabile, ... BMC Infectious Diseases 23 (1), 133 , 2023 2023.0 Citations: 3
Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation C Alteri, R Scutari, V Costabile, L Colagrossi, KY La Rosa, E Agolini, ... Scientific Reports 12, 12814 , 2022 2022.0 Citations: 3
